Drug intelligence / Profile preview

ILSMR

Development stage: Preclinical
Lead developer: Microbiotech
Modality: Small Molecules

Overview

ILSMR is a preclinical small molecule drug candidate developed by Microbiotech Co., Ltd., a Japanese biotechnology company. It is characterized as an "Intensifier of β-Lactam drugs-Susceptibility of MRSA," acting as a susceptibility enhancer that restores the efficacy of β-lactam antibiotics against Methicillin-resistant Staphylococcus aureus (MRSA). The compound works by sensitizing resistant strains to conventional antibiotics like oxacillin, potentially providing a new therapeutic strategy for MRSA infections through combination therapy. By targeting the mechanisms that confer resistance to β-lactams, ILSMR aims to expand the utility of existing antimicrobial agents against highly resistant pathogens.

Other names: アイルスマーAirsumarIntensifier of β-Lactam drugs-Susceptibility of MRSA

Beyond the preview

Go deeper on ILSMR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILSMR.

Explore the full profile